Marktanalyse - Ovarian Cancer - Pipeline Review, H2 2016

Global Markets Direct
12.2016
1887 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Ovarian Cancer - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ovarian Cancer — Pipeline Review, H2 2016, provides an overview of the Ovarian Cancer (Oncology) pipeline landscape.

Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 2, 15, 115, 119, 7, 195, 31 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 11, 34 and 8 molecules, respectively.

Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ovarian Cancer (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ovarian Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 13

Ovarian Cancer Overview 14

Therapeutics Development 15

Ovarian Cancer - Therapeutics under Development by Companies 17

Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 41

Ovarian Cancer - Pipeline Products Glance 44

Ovarian Cancer - Products under Development by Companies 48

Ovarian Cancer - Products under Investigation by Universities/Institutes 81

Ovarian Cancer - Companies Involved in Therapeutics Development 85

Ovarian Cancer - Therapeutics Assessment 371

Drug Profiles 451

Ovarian Cancer - Dormant Projects 1775

Ovarian Cancer - Discontinued Products 1809

Ovarian Cancer - Product Development Milestones 1816

Appendix 1829





List of Tables

Number of Products under Development for Ovarian Cancer, H2 2016 72

Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 75

Number of Products under Development by Companies, H2 2016 (Contd..1) 76

Number of Products under Development by Companies, H2 2016 (Contd..2) 77

Number of Products under Development by Companies, H2 2016 (Contd..3) 78

Number of Products under Development by Companies, H2 2016 (Contd..4) 79

Number of Products under Development by Companies, H2 2016 (Contd..5) 80

Number of Products under Development by Companies, H2 2016 (Contd..6) 81

Number of Products under Development by Companies, H2 2016 (Contd..7) 82

Number of Products under Development by Companies, H2 2016 (Contd..8) 83

Number of Products under Development by Companies, H2 2016 (Contd..9) 84

Number of Products under Development by Companies, H2 2016 (Contd..10) 85

Number of Products under Development by Companies, H2 2016 (Contd..11) 86

Number of Products under Development by Companies, H2 2016 (Contd..12) 87

Number of Products under Development by Companies, H2 2016 (Contd..13) 88

Number of Products under Development by Companies, H2 2016 (Contd..14) 89

Number of Products under Development by Companies, H2 2016 (Contd..15) 90

Number of Products under Development by Companies, H2 2016 (Contd..16) 91

Number of Products under Development by Companies, H2 2016 (Contd..17) 92

Number of Products under Development by Companies, H2 2016 (Contd..18) 93

Number of Products under Development by Companies, H2 2016 (Contd..19) 94

Number of Products under Development by Companies, H2 2016 (Contd..20) 95

Number of Products under Development by Companies, H2 2016 (Contd..21) 96

Number of Products under Development by Companies, H2 2016 (Contd..22) 97

Number of Products under Investigation by Universities/Institutes, H2 2016 98

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 99

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 100

Comparative Analysis by Late Stage Development, H2 2016 101

Comparative Analysis by Clinical Stage Development, H2 2016 102

Comparative Analysis by Early Stage Development, H2 2016 103

Comparative Analysis by Unknown Stage Development, H2 2016 104

Products under Development by Companies, H2 2016 105

Products under Development by Companies, H2 2016 (Contd..1) 106

Products under Development by Companies, H2 2016 (Contd..2) 107

Products under Development by Companies, H2 2016 (Contd..3) 108

Products under Development by Companies, H2 2016 (Contd..4) 109

Products under Development by Companies, H2 2016 (Contd..5) 110

Products under Development by Companies, H2 2016 (Contd..6) 111

Products under Development by Companies, H2 2016 (Contd..7) 112

Products under Development by Companies, H2 2016 (Contd..8) 113

Products under Development by Companies, H2 2016 (Contd..9) 114

Products under Development by Companies, H2 2016 (Contd..10) 115

Products under Development by Companies, H2 2016 (Contd..11) 116

Products under Development by Companies, H2 2016 (Contd..12) 117

Products under Development by Companies, H2 2016 (Contd..13) 118

Products under Development by Companies, H2 2016 (Contd..14) 119

Products under Development by Companies, H2 2016 (Contd..15) 120

Products under Development by Companies, H2 2016 (Contd..16) 121

Products under Development by Companies, H2 2016 (Contd..17) 122

Products under Development by Companies, H2 2016 (Contd..18) 123

Products under Development by Companies, H2 2016 (Contd..19) 124

Products under Development by Companies, H2 2016 (Contd..20) 125

Products under Development by Companies, H2 2016 (Contd..21) 126

Products under Development by Companies, H2 2016 (Contd..22) 127

Products under Development by Companies, H2 2016 (Contd..23) 128

Products under Development by Companies, H2 2016 (Contd..24) 129

Products under Development by Companies, H2 2016 (Contd..25) 130

Products under Development by Companies, H2 2016 (Contd..26) 131

Products under Development by Companies, H2 2016 (Contd..27) 132

Products under Development by Companies, H2 2016 (Contd..28) 133

Products under Development by Companies, H2 2016 (Contd..29) 134

Products under Development by Companies, H2 2016 (Contd..30) 135

Products under Development by Companies, H2 2016 (Contd..31) 136

Products under Development by Companies, H2 2016 (Contd..32) 137

Products under Investigation by Universities/Institutes, H2 2016 138

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 139

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 140

Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 141

Ovarian Cancer - Pipeline by 3-V Biosciences Inc, H2 2016 142

Ovarian Cancer - Pipeline by 4SC AG, H2 2016 143

Ovarian Cancer - Pipeline by AB Science SA, H2 2016 144

Ovarian Cancer - Pipeline by AbbVie Inc, H2 2016 145

Ovarian Cancer - Pipeline by AbGenomics International Inc, H2 2016 146

Ovarian Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016 147

Ovarian Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016 148

Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 149

Ovarian Cancer - Pipeline by Aduro BioTech Inc, H2 2016 150

Ovarian Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2016 151

Ovarian Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016 152

Ovarian Cancer - Pipeline by Advaxis Inc, H2 2016 153

Ovarian Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016 154

Ovarian Cancer - Pipeline by Aeterna Zentaris Inc, H2 2016 155

Ovarian Cancer - Pipeline by Alchemia Ltd, H2 2016 156

Ovarian Cancer - Pipeline by Alethia Biotherapeutics Inc, H2 2016 157

Ovarian Cancer - Pipeline by Almac Discovery Ltd, H2 2016 158

Ovarian Cancer - Pipeline by Alpha Cancer Technologies Inc, H2 2016 159

Ovarian Cancer - Pipeline by Alteogen Inc, H2 2016 160

Ovarian Cancer - Pipeline by Ambrx Inc, H2 2016 161

Ovarian Cancer - Pipeline by Amgen Inc, H2 2016 162

Ovarian Cancer - Pipeline by Anavex Life Sciences Corp, H2 2016 163

Ovarian Cancer - Pipeline by ANP Technologies Inc, H2 2016 164

Ovarian Cancer - Pipeline by AntiCancer Inc, H2 2016 165

Ovarian Cancer - Pipeline by Antoxis Ltd, H2 2016 166

Ovarian Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016 167

Ovarian Cancer - Pipeline by Aphios Corp, H2 2016 168

Ovarian Cancer - Pipeline by Aposense Ltd, H2 2016 169

Ovarian Cancer - Pipeline by Aprea AB, H2 2016 170

Ovarian Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016 171

Ovarian Cancer - Pipeline by arGEN-X BV, H2 2016 172

Ovarian Cancer - Pipeline by ARMO Biosciences Inc, H2 2016 173

Ovarian Cancer - Pipeline by Armour Therapeutics Inc, H2 2016 174

Ovarian Cancer - Pipeline by Arno Therapeutics Inc, H2 2016 175

Ovarian Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016 176

Ovarian Cancer - Pipeline by ArQule Inc, H2 2016 177

Ovarian Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 178

Ovarian Cancer - Pipeline by Arvinas Inc, H2 2016 179

Ovarian Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H2 2016 180

Ovarian Cancer - Pipeline by Astellas Pharma Inc, H2 2016 181

Ovarian Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016 182

Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2016 183

Ovarian Cancer - Pipeline by Atara Biotherapeutics Inc, H2 2016 184

Ovarian Cancer - Pipeline by Athenex Inc, H2 2016 185

Ovarian Cancer - Pipeline by ATLAB Pharma SAS, H2 2016 186

Ovarian Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 187

Ovarian Cancer - Pipeline by Avipep Pty Ltd, H2 2016 188

Ovarian Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016 189

Ovarian Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016 190

Ovarian Cancer - Pipeline by Bavarian Nordic A/S, H2 2016 191

Ovarian Cancer - Pipeline by Bayer AG, H2 2016 192

Ovarian Cancer - Pipeline by BeiGene Ltd, H2 2016 193

Ovarian Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016 194

Ovarian Cancer - Pipeline by BioCancell Ltd, H2 2016 195

Ovarian Cancer - Pipeline by BioMoti Ltd, H2 2016 196

Ovarian Cancer - Pipeline by Bionomics Ltd, H2 2016 197

Ovarian Cancer - Pipeline by BioNTech AG, H2 2016 198

Ovarian Cancer - Pipeline by Biscayne Pharmaceuticals Inc, H2 2016 199

Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016 200

Ovarian Cancer - Pipeline by Boston Biomedical Inc, H2 2016 201

Ovarian Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016 202

Ovarian Cancer - Pipeline by Calithera Biosciences Inc, H2 2016 203

Ovarian Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016 204

Ovarian Cancer - Pipeline by Cavion LLC, H2 2016 205

Ovarian Cancer - Pipeline by Cellceutix Corp, H2 2016 206

Ovarian Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016 207

Ovarian Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016 208

Ovarian Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016 209

Ovarian Cancer - Pipeline by Celon Pharma SA, H2 2016 210

Ovarian Cancer - Pipeline by Celprogen Inc, H2 2016 211

Ovarian Cancer - Pipeline by Celsion Corp, H2 2016 212

Ovarian Cancer - Pipeline by Celyad SA, H2 2016 213

Ovarian Cancer - Pipeline by Ceronco Biosciences, H2 2016 214

Ovarian Cancer - Pipeline by CerRx Inc, H2 2016 215

Ovarian Cancer - Pipeline by Cerulean Pharma Inc, H2 2016 216

Ovarian Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016 217

Ovarian Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016 218

Ovarian Cancer - Pipeline by Clovis Oncology Inc, H2 2016 219

Ovarian Cancer - Pipeline by CohBar Inc, H2 2016 220

Ovarian Cancer - Pipeline by Coherus BioSciences Inc, H2 2016 221

Ovarian Cancer - Pipeline by Commence Bio Inc, H2 2016 222

Ovarian Cancer - Pipeline by Compliment Corp, H2 2016 223





List of Figures

Number of Products under Development for Ovarian Cancer, H2 2016 72

Number of Products under Development for Ovarian Cancer - Comparative Analysis, H2 2016 73

Number of Products under Development by Companies, H2 2016 74

Number of Products under Investigation by Universities/Institutes, H2 2016 98

Comparative Analysis by Late Stage Development, H2 2016 101

Comparative Analysis by Clinical Stage Development, H2 2016 102

Comparative Analysis by Early Stage Products, H2 2016 103

Assessment by Monotherapy Products, H2 2016 428

Assessment by Combination Products, H2 2016 429

Number of Products by Top 10 Targets, H2 2016 430

Number of Products by Stage and Top 10 Targets, H2 2016 430

Number of Products by Top 10 Mechanism of Actions, H2 2016 465

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 465

Number of Products by Top 10 Routes of Administration, H2 2016 504

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 504

Number of Products by Top 10 Molecule Types, H2 2016 506

Number of Products by Stage and Top 10 Molecule Types, H2 2016 506

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus